|CLVS -- USA Stock|| |
USD 47.87 0.83 1.76%
Mr. Erle T. Mast is no longer Chief Financial Officer Executive Vice President of Clovis Oncology Inc. effective March 31 2016. He is one of the cofounders. Previously Mr. Mast served in the same role at Pharmion Corporationrationration beginning in 2002. From 1997 through 2002 Mr. Mast worked for Dura Pharmaceuticals Inc. and its successor Elan Corporationrationration. From 2000 to 2002 he served as Chief Financial Officer for the Global Biopharmaceuticals business unit for Elan. From 1997 to 2000 Mr. Mast served as Vice President of Finance for Dura Pharmaceuticals. Prior to that Mr. Mast was a partner with Deloitte Touche LLP. Mr. Mast also serves on the board of directors of Zogenix Inc. and Receptos Inc.
Age: 51 Founder Since 2009
Mast received a B.Sc. in business administration from California State University Bakersfield.
Erle Mast Latest Insider Activity
The company has return on total asset (ROA)
of (25.72) %
which means that it has lost $25.72 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (152.2) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 282.73 M in liabilities with Debt to Equity (D/E) ratio of 92.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clovis Oncology has Current Ratio of 6.42 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado. Clovis Oncology operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 360 people.Clovis Oncology (CLVS) is traded on BATS Exchange in USA. It is located in COLORADO U.S.A and employs 360 people. Clovis Oncology is listed under Pharmaceutical Products category by Fama And French industry classification.
Clovis Oncology Leadership Team
|James Blair, Independent Director|
|James Barrett, Independent Chairman of the Board|
|Thorlef Spickschen, Independent Director|
|Brian Atwood, Independent Director|
|Edward McKinley, Independent Director|
|Paul Klingenstein, Independent Director|
|Dale Hooks, Senior Vice President Chief Commercial Officer|
|MB BSc, Chief Medical Officer and Executive VP of Clinical and Preclinical Devel. and Pharmacovigilance|
|Keith Flaherty, Director|
|Lindsey Rolfe, Chief Medical Officer, Executive Vice President - Clinical and Preclinical Development & Pharmacovigilance|
|Breanna Burkart, Sr. Director of Investor Relations|
|Steven Hoerter, Chief Commercial Officer and Executive VP|
|Erle Mast, Co-Founder, CFO, Executive VP and Secretary|
|Patrick Mahaffy, President CEO, Director|
|Ginger Graham, Independent Director|
|Gillian IversRead, Executive Vice President - Technical Operations, Chief Regulatory Officer|
|Michael Barrett, Independent Chairman of the Board|
|Daniel Muehl, Principal Financial Officer, Principal Accounting Officer|
Stock Performance Indicators
Most of Macroaxis users are currently bullish on Clovis Oncology. What is your opinion about investing in Clovis Oncology? Are you bullish or bearish?
and pair trading evaluation for Clovis Oncology and China Cord Blood
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return